NCT07144306Recruiting
AI-Driven Early Detection of Skin Cancer
Source: ClinicalTrials.gov · Last updated 26 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 20 Aug 2025
- Start date
- 1 Oct 2025
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- Nuvana Healthcare LTD
- Diseases
- Melanoma, Childhood cancers
- NCT number
- NCT07144306
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Oct 2025 to the primary completion date, 1 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Inability to provide informed consent.
- Poor-quality images unsuitable for AI analysis.
Who the study is looking for
- Adults (≥18 years) presenting with skin lesions suspicious for malignancy.
- Ability to provide informed consent.
Age in the registry: 18 months to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nuvana Healthcare Ltd Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.